Výsledky vyhledávání

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

[Surgical interventions in patients with myeloproliferative disease--prophylaxis and treatment of haemostatic disorders]

Autor: P, Dulícek, J, Voglová, J, Malý

Publikováno v: Vnitrni lekarstvi. 56(1)

Despite many decades of laboratory and clinical research of pathogenesis bleeding and thrombosis and the search for the identification of the risk factors, the accomplished results are unsatisfactory in clinical praxis. In our article, we discuss inc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::fbc40d5495a224dd52d1b59beecbb032
https://pubmed.ncbi.nlm.nih.gov/20184114

Zobrazit plný text záznamu

[The results of patients with essentials thrombocythemia and other myeloproliferation-related thrombocythemia--a report of patients treated with Thromboreductin]

Publikováno v: Vnitrni lekarstvi. 55(11)

The registry of patients treated with Thromboreductin (anagrelide) in the Czech Republic contains data concerning patients that have been treated using this drug since 2004. As of June 2009, the total number of patients was 549. The current analysis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::28dc68f7822efebcd25645ab17ee454d
https://pubmed.ncbi.nlm.nih.gov/20017445

Zobrazit plný text záznamu

[What is the current treatment of patients with essential thrombocytopenia and other myeloproliferations accompanied with thrombocythemia [corrected] and what can be the predictive sign of the risk of thrombosis in such patients--a report from the registry of patients treated by Thromboreductine]

Autor: M, Penka, J, Schwarz, T, Pavlík, R, Pytiĺk, M, Doubek, P, Dulícek, J, Kissová, A, Hlusi, M, Schutzová, O, Cerná, Y, Brychtová, T, Szotkowski, Z, Volková, J, Seghetová, V, Vozobulová, I, Hadacová, I, Hochová, J, Voglová, L, Dusek

Publikováno v: Vnitrni lekarstvi. 54(7-8)

The registry of patients treated with Thromboreductine (anagrelid) in the contributing centres in the Czech Republic has been updated with data on the patients receiving this medication since 2004. The original purpose of the registry was to record r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::9c1b372f34b114217f122f50ab0402e9
https://pubmed.ncbi.nlm.nih.gov/18780577

Zobrazit plný text záznamu

[Essential thrombocytemia and other myeloproliferations with thrombocytemia in the data of the register of patients treated with Thromboreductin till the end of 2006]

Publikováno v: Vnitrni lekarstvi. 53(6)

Since 2005, registers of patients treated with Thromboreductin (anagrelid) kept by some centres in the Czech Republic have been supplied with data concerning patients whose treatment with this preparation started in 2004. The purpose of the register

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::0ed06f6868d99945c954dd6bc258ea34
https://pubmed.ncbi.nlm.nih.gov/17702125

Zobrazit plný text záznamu

Is FLT3 internal tandem duplication significant indicator for allogeneic transplantation in acute myeloid leukemia? An analysis of patients from the Czech Acute Leukemia Clinical Register (ALERT)

Autor: M, Doubek, J, Muzík, T, Szotkowski, V, Koza, P, Cetkovský, T, Kozák, P, Zák, J, Voglová, S, Struncová, L, Dusek, K, Indrák

Publikováno v: Neoplasma. 54(1)

To assess the prognostic relevance of activating mutations of FLT3 gene on outcome of allogeneic transplantations in AML patients, we performed an analysis of all patients with FLT3 mutations registered in the Czech Acute Leukemia Clinical Register (

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::56386b1f6dc61a23dd2687b47a0e8275
https://pubmed.ncbi.nlm.nih.gov/17233551

Zobrazit plný text záznamu

[Combination of imatinib and anagrelide in treatment of chronic myeloid leukemia in blastic phase]

Autor: J, Voglová, V, Maisnar, M, Beránek, L, Chrobák

Publikováno v: Vnitrni lekarstvi. 52(9)

Chronic myeloid leukemia in blast phase (BP) is resistant to chemotherapy and majority of patients die within 6 months. Inhibitor Bcr-Abl tyrosine kinase imatinib mesylate dramatically improved outcome of patients in chronic phase (CP) and is also ef

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::d2e2c5bb015ea65cca3a991d9093aba6
https://pubmed.ncbi.nlm.nih.gov/17091608

Zobrazit plný text záznamu

[Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR]

Publikováno v: Vnitrni lekarstvi. 52(5)

Anagrelide hydrochloride is an effective drug used in patients with ET and other myeloproliferative disorders with thrombocythemia to selectively decrease the number of thrombocytes. Indications for use of anagrelide were described in detail in Czech

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5ef80b222b161e5802baaa259833b4fc
https://pubmed.ncbi.nlm.nih.gov/16771099

Zobrazit plný text záznamu

[Importance of quantitative evaluation of BCR-ABL transcripts using real-time PCR for effective treatment of chronic myeloid leukemia]

Autor: M, Beránek, J, Voglová, A, Sýkorová, D, Belada, M, Bláha

Publikováno v: Casopis lekaru ceskych. 145(1)

Molecular biology methods based on reverse transcription and polymerase chain reaction (RT-PCR) are able to detect the presence of BCR-ABL transcripts in chronic myeloid leukemia (CML). In this study we present our experience with monitoring of resid

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::98ed5c29b7e1840315c430f6c09e6b32
https://pubmed.ncbi.nlm.nih.gov/16468238

Zobrazit plný text záznamu

[The idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia]

Autor: L, Chrobák, J, Voglová

Publikováno v: Vnitrni lekarstvi. 51(12)

Idiopathic hypereosinophilic syndrome is a heterogenous group of hematological disorders characterized by eosinophilia (1.5 x 10(9)/l) persistent for more than 6 months, exclusion of reactive eosinophilia from other causes, such as parasitic infectio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::19578cebc3ec165eee3aa807cf3b9a11
https://pubmed.ncbi.nlm.nih.gov/16430106

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání